Novo Nordisk has launched a lawsuit against telehealth provider Hims & Hers Health, accusing the company of promoting and selling compounded versions of its blockbuster obesity drug Wegovy without regulatory approval. The case represents a sharp escalation in an ongoing dispute over the growing market for lower-cost alternatives to branded weight-loss medications in the United States.
According to court filings, Novo Nordisk is seeking a permanent injunction that would block Hims & Hers from distributing compounded drugs that allegedly infringe on its patents. The Danish pharmaceutical company is also requesting financial compensation, arguing that the sale of these alternatives amounts to unfair competition and violates intellectual property protections.
Novo executives have raised concerns about the safety and oversight of compounded medications. Company representatives argue that unlike FDA-approved treatments, compounded drugs do not undergo the same level of testing and regulatory review for quality, safety, and effectiveness. Novo maintains that widespread marketing of such products could expose patients to avoidable risks and undermine confidence in approved therapies.
Hims & Hers Pulls Back New Copycat Pill Amid Scrutiny
The legal action follows an announcement from Hims & Hers that it would stop offering a recently introduced compounded obesity pill. The company’s decision came after increased attention from federal regulators and mounting legal pressure from Novo Nordisk. Hims had planned to market the oral drug at a significantly lower introductory price, positioning it as a more affordable alternative to Wegovy.
In its public response to the lawsuit, Hims & Hers defended its business model and criticized Novo Nordisk’s legal strategy. The telehealth company argued that compounded medications play an important role in expanding access to treatment, particularly for patients seeking more affordable or customized options. Hims said its services are designed to provide personalized healthcare and emphasized its experience in delivering telehealth solutions to a broad patient base.
Investors reacted quickly to the dispute. Shares of Novo Nordisk rose after news of the lawsuit became public, while Hims & Hers saw a sharp decline in its stock price on the New York Stock Exchange. The market response reflected uncertainty about how the legal battle and potential regulatory action could affect Hims’ future operations.
Competition Heats Up in the Weight-Loss Drug Market
The lawsuit arrives at a time of intense competition in the rapidly expanding obesity drug sector. Novo Nordisk is working to defend its market position as demand for weight-loss medications continues to surge. The company faces competition not only from rival drugmakers such as Eli Lilly but also from a wave of compounded alternatives offered by telehealth companies and specialized pharmacies.
These alternatives became more common during previous shortages of branded drugs. U.S. regulations allow pharmacies to produce compounded versions of patented medications when approved products are unavailable or in limited supply. However, Novo Nordisk says that supply constraints for semaglutide — the active ingredient in Wegovy and several of its injectable treatments — have largely been resolved in the United States.
The company has expanded its manufacturing capacity, and no shortages have been reported for the Wegovy pill since its recent launch. Despite improved availability, Novo estimates that around 1.5 million Americans continue to use compounded GLP-1 medications, a class of drugs that includes semaglutide and has become highly popular for weight management.
Hims & Hers has acknowledged that its compounded products contain semaglutide, which remains protected by U.S. patents until 2032. The company argues that its offerings are legal because they are tailored to individual patients. Novo disputes that claim, asserting that large-scale production marketed as personalization falls outside the intended scope of compounding rules. The pharmaceutical company says legitimate compounding should occur only when there is a clear medical need for customization, not as a substitute for mass-produced branded drugs.
FDA Weighs Enforcement Measures
Federal regulators are also examining the situation. The U.S. Food and Drug Administration has indicated it is preparing legal action related to Hims & Hers’ compounded obesity pill. Potential steps could include limiting the company’s access to pharmaceutical ingredients and referring the matter to the Department of Justice to review possible violations of federal law.
Novo Nordisk has pointed out that some telehealth providers are shifting toward distributing FDA-approved medications instead of compounded substitutes. The company argues that stronger enforcement may be necessary to ensure that telehealth platforms comply with pharmaceutical regulations and intellectual property laws.
